Puncture Robotic, a Shanghai-based developer of medical robots, has reportedly raised RMB 100 million (USD 13.9 million) in a Series A+ financing round. The round was led by Shenzhen Capital Group, with participation from Huayi Capital. The funds raised will be allocated towards product research and development, clinical validation, enhancement of manufacturing capacity, and global promotion efforts.
Expanding Pipeline and Innovation in Medical Robotics
Incubated by HIT Robot Group (HRG) in 2019, Puncture Robotic has an impressive product pipeline that spans serious medicine and medical aesthetics. The company’s offerings include hair transplant robots and surgical robot puncture navigation systems, among others. This latest funding round will enable Puncture Robotic to further develop its innovative medical robotics solutions and expand its reach in the global market.
Investment in Research and Clinical Validation
The proceeds from the Series A+ financing round will be instrumental in advancing the company’s research and development efforts, ensuring that its products meet the highest standards of clinical validation. This investment will also support the enhancement of Puncture Robotic’s manufacturing capabilities, allowing the company to scale up production to meet growing demand.
Global Promotion and Market Expansion
With a strong focus on global promotion, Puncture Robotic aims to increase awareness of its innovative medical robotics solutions and expand its market presence. The funding will play a crucial role in the company’s international growth strategy, positioning Puncture Robotic as a leader in the medical robotics sector.-Fineline Info & Tech
